This clinical trial will study a drug known as CAEL-101. CAEL-101 is a monoclonal antibody. The purpose of the study is to learn if CAEL-101 helps people with AL amyloidosis that has affected their hearts to live longer.
Thank you for your interest, but this study is not currently enrolling.
North Carolina (Statewide)
Sascha Tuchman
LCCC - Clinical Trials
Clinical or Medical
Interventional
Blood Conditions
Cancer (Multiple Myeloma)
20-1745
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
